RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals to Present at Investor Conferences in September

28 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

07 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

04 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

01 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

19 июл 2023 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

17 июл 2023 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 июл 2023 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

17 июн 2023 14:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

07 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 июн 2023 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

22 май 2023 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

08 май 2023 08:00:08 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

05 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

02 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

24 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023

18 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

10 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 апр 2023 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

27 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire